The following article is a part of conference coverage from the European Alliance of Associations for Rheumatology (EULAR) 2021 Virtual Congress, held online from June 2 to 5, 2021. The team at Rheumatology Advisor will be reporting on the latest news and research conducted by leading experts in rheumatology.
Although patients with psoriatic arthritis with axial involvement (axial PsA) and patients with axial spondyloarthritis (axSpA) present with common clinical characteristics, meaningful differences in these patient populations may exist, according to study findings presented at the European Alliance of Associations for Rheumatology (EULAR) 2021 Virtual Congress, held from June 2 to 5, 2021.
Study authors conducted a real-world analysis to compare the characteristics of patients with axial PsA and axSpA.
The prospective, multicenter, observational study for the CORRONA (now CorEvitas) PsA/SpA Registry included adult patients with axial PsA or axSpA from March 2013 to August 2020. Data compared between the 2 patients groups included enrollment visit demographics, clinical characteristics, treatment history, measures of disease activity, and patient-reported outcomes.
Of the 1044 patients included in the study, 470 had axial PsA and 574 patients had axSpA. Compared with patients in the axSpA group, patients in the axial PsA group were more likely to be women and older. Patients with axial PsA vs axSpA group also had a shorter time since symptom onset (12.0 vs 15.6 years, respectively; P <.001) and time since diagnosis (6.8 vs 8.3 years, respectively; P =.01).
Compared with patients with axSpA, patients with axial PsA were less likely to have current or historical uveitis (14% vs 4%, respectively; P <.001) or inflammatory bowel disease (10% vs 5%; P =.005).
Compared with patients with axSpA, patients with axial PsA had a higher prevalence of previous biologic and conventional synthetic disease-modifying antirheumatic drug use (P <.001 for both); however, mean dactylitis and enthesitis counts were higher among patients with axial PsA (P <.001 for both).
While average patient-reported pain and spinal pain was lower among patients in the axial PsA group compared with the axSpA group (pain, P =.015; spinal pain, P <.001), patient reports for morning stiffness, mean fatigue at work, and impairment scores were similar between both the patient groups.
“Findings from this descriptive real-world analysis suggest there may be meaningful differences between [patients] with [axSpA] and axial PsA but future studies are needed to better understand these differences,” the study authors concluded.
Disclosure: Multiple authors declared affiliations with industry. Please refer to the original article for a full list of disclosures.
Visit Rheumatology Advisor’s conference section for coverage of the EULAR 2021 Virtual Congress.
Mease PJ, Marchese M, Mclean R, et al. Comparison of baseline disease activity and patient (PT)-reported outcomes (PROS) between PTs with psoriatic arthritis and axial involvement (axial PsA) and axial spondyloarthritis (axial SpA) from the Corrona PSA/SPA Registry. Presented at: EULAR 2021 Virtual Congress; June 2-5, 2021. Abstract OP0049.